MBX Biosciences (MBX) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MBX Biosciences (MBX) has outperformed UroGen Pharma (URGN) over the past year, gaining 235.8% versus a gain of 113.4%. MBX Biosciences is the larger company by market cap ($2.56 billion vs $1.82 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | URGN |
|---|---|---|
| Share price | $53.14 | $37.25 |
| Market cap | $2.56B | $1.82B |
| 1-day change | -0.22% | +0.73% |
| YTD return | +68.83% | +57.90% |
| 1-year return | +235.75% | +113.39% |
| 5-year return | — | +117.27% |
| Forward P/E | — | 13.33 |
| EPS (TTM) | $-2.37 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | $-87.00M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $72.64 | $50.81 |
| 52-week low | $12.94 | $15.86 |
| Distance from 52-week high | -26.85% | -26.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.47% | +61.07% |
| Average volume | 534.13K | 849.01K |
| Shares outstanding | 48.16M | 48.88M |
| Employees | 63 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed URGN by 122.4 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
MBX vs URGN FAQ
Which is bigger, MBX Biosciences or UroGen Pharma?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.56B compared with $1.82B for UroGen Pharma (URGN).
Which stock has performed better over the past year, MBX or URGN?
MBX returned +235.75% over the past 12 months, compared with +113.39% for URGN (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.